LDR Holding Corp CFO Sells $543,800 in Stock (LDRH)
LDR Holding Corp (NASDAQ:LDRH) CFO Robert Mcnamara sold 20,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $27.19, for a total value of $543,800.00. Following the sale, the chief financial officer now directly owns 346 shares in the company, valued at approximately $9,408. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of research firms have recently commented on LDRH. Analysts at Piper Jaffray raised their price target on shares of LDR Holding Corp from $38.00 to $40.00 in a research note on Thursday, August 7th. They now have an “overweight” rating on the stock. Analysts at RBC Capital initiated coverage on shares of LDR Holding Corp in a research note on Monday, June 23rd. They set an “outperform” rating and a $34.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $35.50.
LDR Holding Corp (NASDAQ:LDRH) traded up 4.24% during mid-day trading on Friday, hitting $27.07. The stock had a trading volume of 472,620 shares. LDR Holding Corp has a 52-week low of $17.79 and a 52-week high of $40.39. The stock has a 50-day moving average of $23.67 and a 200-day moving average of $26.67. The company’s market cap is $702.9 million.
LDR Holding Corp (NASDAQ:LDRH) last released its earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.05. The company had revenue of $34.80 million for the quarter, compared to the consensus estimate of $31.14 million. LDR Holding Corp’s revenue was up 30.8% compared to the same quarter last year. Analysts expect that LDR Holding Corp will post $-0.62 EPS for the current fiscal year.
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and surgical technologies for the treatment of patients suffering from spine disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.